A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial

European Journal of Cancer

Volumn 51, Issue 10, 2015, Pages 1312-1320

  Bui Nguyen, B ^a   Butrynski, J E ^b   Penel, N ^c   Blay, J Y ^d   Isambert, N ^e   Milhem, M ^f   Kerst, J M ^g   Reyners, A K L ^h   Litiere S ⁱ   Marreaud S ⁱ   Collin, F ^e   Van Der Graaf, W T A ^j  

^a INSTITUT BERGONIÉ   (France)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c CENTRE OSCAR LAMBRET   (France)

^d UNIVERSITÉ LYON 1   (France)

^e CENTRE GEORGES FRANÇOIS LECLERC   (France)

^f UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^g NETHERLANDS CANCER INSTITUTE   (Netherlands)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ EORTC DATA CENTER   (Belgium)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Clinical trial; Doxorubicin; First line chemotherapy; Metastatic; Soft tissue sarcoma; Trabectedin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DOXORUBICIN; GAMMA GLUTAMYLTRANSFERASE; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; ANTINEOPLASTIC ANTIBIOTIC; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPARATIVE STUDY; CONTROLLED STUDY; DEHYDRATION; DETERIORATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEALTH STATUS; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPONATREMIA; INFECTION; KIDNEY DISEASE; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; METASTASIS; MULTICENTER STUDY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; SOFT TISSUE SARCOMA; THORAX DISEASE; THROMBOCYTOPENIA; UROGENITAL TRACT DISEASE; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SARCOMA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SARCOMA; TETRAHYDROISOQUINOLINES;

EID: 84930678267     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.03.023     Document Type: Article

References (17)

1. S. Movva, and C. Verschraegen Systemic management strategies for metastatic soft tissue sarcoma Drugs 71 2011 2115 2129
2. Judson I, Verweij J, Gelderblom H, et al. Results of a randomised phase III trial (EORTC 62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as first line chemotherapy for patients with advanced or metastatic soft tissue sarcoma: a survival study by the EORTC Soft Tissue Sarcoma Group; 2012.
3. S. Delaloge, A. Yovine, and A. Taamma Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients - preliminary evidence of activity J Clin Oncol 19 2001 1248 1255
4. R. Garcia-Carbonero, J.G. Supko, and J. Manola Phase II and pharmacokinetic study of Ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy J Clin Oncol 22 2004 1480 1490
5. A. Le Cesne, J.Y. Blay, and I. Judson Phase II study of Et-743 in advanced soft tissue sarcomas: a european organisation for the research and treatment of cancer (EORTC) soft tissue and bone sarcoma group trial J Clin Oncol 23 2005 576 584
6. A. Yovine, M. Riofrio, and J.Y. Blay Phase II study of Ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients J Clin Oncol 22 2004 890 899
7. G.D. Demetri, S.P. Chawla, and M.M. Von Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules J Clin Oncol 27 2009 4188 4196
8. M. Van Glabbeke, J. Verweij, and I. Judson Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas Eur J Cancer 38 2002 543 549
9. Yovine A, Casali P, Grosso F, et al. Trabectedin 3-hour infusion every 3 weeks in pre-treated advanced sarcoma patients: a compassionate-use administration experience. In: Joint ECCO 15-34th ESMO multidisciplinary congress, Berlin, 20-24 September 2009. Eur J Cancer; 7 (Issue 2):597-598; 2009 (Abs 9426).
10. Chawla SP, Italiano A, Patel SR, et al. Safety of trabectedin versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients with translocation-related sarcoma (TRS). In: European cancer congress; 2013 (Abstr).
11. R. Garcia-Carbonero, J.G. Supko, and R.G. Maki Ecteinascidin-743 (Et-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study J Clin Oncol 23 2005 5484 5492
12. A. Le Cesne, S. Cresta, and R.G. Maki A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas Eur J Cancer 48 2012 3036 3044
13. J.Y. Blay, A. Italiano, and I. Ray-Coquard Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program BMC Cancer 13 2013 64
14. A. Gronchi, B.N. Bui, and S. Bonvalot Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma Ann Oncol 23 2012 771 776
15. A. Le Cesne, A. Yovine, and J.Y. Blay A retrospective pooled analysis of trabectedin safety in 1132 patients with solid tumors treated in phase II clinical trials Invest New Drugs 30 2012 1193 1202
16. A. Italiano, A. Laurand, and A. Laroche ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma Cancer 117 2011 3445 3456
17. P. Schoffski, M. Taron, and J. Jimeno Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study Eur J Cancer 47 2011 1006 1012